dlerick/iStock via Getty Images Shares of Artelo Biosciences ( NASDAQ: ARTL ) jumped 13% in early trading Monday on news that the FDA has cleared the company to begin human clinical trials of its drug candidate ART26.12 for the treatment of chemotherapy-induced peripheral neuropathy. Artelo has been developing the drug as a non-opioid option for the management of painful neuropathies.
The company expects to have Phase 1 results in the first half of 2025. More on Artelo Biosciences Seeking Alpha’s Quant Rating on Artelo Biosciences Historical earnings data for Artelo Biosciences Financial information for Artelo Biosciences.
